DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages
Authors: Dr Claudia Hadlow, Medical Officer, John Hunter Hospital, Newcastle, NSW, Australia; Dr Matthew James Verheyden, Medical Officer, Royal North Shore Hospital, Sydney, NSW, Australia; Dr Paul Chee, Consultant Dermatologist and Director of Dermatology at the John Hunter Hospital and the Royal Newcastle Centre, NSW, Australia. DermNet NZ Editor in Chief: Adjunct A/Prof Amanda Oakley, Dermatologist, Hamilton, New Zealand. Copy edited by Gus Mitchell. July 2020.
Cockayne syndrome is a genetic degenerative disorder first described by E. Cockayne in 1936 [1,2]. It is classified into three clinical subtypes based on the severity of disease and the age of presentation:
Cockayne syndrome is rare, with a prevalence of 2.5 per million with only around 180 cases reported in the literature worldwide. It has been described in both sexes and in people from varied racial backgrounds .
A sibling of a child with Cockayne syndrome has a 25% chance of having the disease .
Cockayne syndrome is an inherited autosomal recessive disorder. For an individual to express the phenotype, their genotype must comprise of two recessive alleles, one from each parent .
Mutations occur in excision repair cross complementation genes (ERCC) and may arise in the ERCC6 or ERCC8 genes, which code for proteins involved in DNA repair. Mutations to these genes result in defective DNA repair, such as transcription-coupled nucleotide excision repair affecting ribonucleic acid (RNA) synthesis that repairs damage resulting from UV radiation. The result is cell malfunction and apoptosis (bodily-directed cell death).
Cockayne syndrome is a multisystem disorder with variable severity.
The cutaneous features of Cockayne syndrome are:
Other features of Cockayne syndrome include:
The ERCC6 and ERCC8 gene mutations of Cockayne syndrome cause progressive cellular dysfunction and apoptosis across multiple organ systems.
People with Cockayne syndrome experience severe liver failure and may die if exposed to the drug metronidazole .
Cockayne syndrome is not associated with an increased risk of cancer .
Cockayne syndrome is diagnosed with the presence of clinical features, which become more obvious over time due to the progressive nature of the disease.
The diagnosis is confirmed by genetic testing. Targeted single gene sequencing and extended genetic panels are available to identify whether the patient has both pathogenic allele variants in ERCC6 or ERCC8.
Prenatal diagnosis of Cockayne syndrome involves gene sequencing from chorionic villous sampling (sampling of the placental tissue) and amniotic fluid cultures .
Prospective parents can also undergo molecular genetic testing for carrier status prior to conception .
The differential diagnoses for Cockayne syndrome will vary according to the presenting features of the individual patient .
Xeroderma pigmentosum is due to defective global genomic nucleotide excision repair. It presents with sun sensitivity, sunlight-induced ocular complications, and an increased risk of cutaneous neoplasms. It does not cause growth retardation. Pigmentary changes are more prominent in xeroderma pigmentosum than in Cockayne syndrome. One in four people with xeroderma pigmentosum has neurological symptoms .
Rothmund-Thomson syndrome is characterised by poikiloderma on the face, extremities, and buttocks. It also causes photosensitivity.
Bloom syndrome causes growth retardation and erythema of the hands and feet. Neurological and cognitive development is normal.
There is no cure for Cockayne syndrome. Treatment involves supportive measures, including photoprotection, optimisation of nutrition, physiotherapy, and occupational therapy.
Children with Cockayne syndrome should undergo at least annual surveillance with the following considerations.
Genetic counselling should be considered by parents of a child with Cockayne syndrome due to the risk for future pregnancies .
Individuals with Cockayne syndrome rarely live past the second to third decade of life due to ambulatory and feeding difficulties associated with neurological degeneration .
Books about skin diseases
© 2020 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.